Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
88.83
-3.49 (-3.78%)
At close: Oct 24, 2024, 4:00 PM
88.50
-0.33 (-0.37%)
After-hours: Oct 24, 2024, 4:00 PM EDT
Axsome Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Axsome Therapeutics stock have an average target of 124.64, with a low estimate of 105 and a high estimate of 180. The average target predicts an increase of 40.31% from the current stock price of 88.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for AXSM stock from 14 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | May '24 | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 |
---|---|---|---|---|---|---|
Strong Buy | 6 | 6 | 7 | 8 | 8 | 8 |
Buy | 5 | 5 | 5 | 5 | 6 | 6 |
Hold | 1 | 1 | 1 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 12 | 12 | 13 | 13 | 14 | 14 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
RBC Capital | RBC Capital | Buy Maintains $130 → $131 | Buy | Maintains | $130 → $131 | +47.47% | Oct 4, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +20.45% | Sep 20, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +20.45% | Sep 16, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +20.45% | Sep 9, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $107 | Buy | Reiterates | $107 | +20.45% | Sep 6, 2024 |
Financial Forecast
Revenue This Year
385.61M
from 270.60M
Increased by 42.50%
Revenue Next Year
652.75M
from 385.61M
Increased by 69.28%
EPS This Year
-5.66
from -5.27
EPS Next Year
-2.01
from -5.66
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 422.1M | 791.1M | 1.8B | ||
Avg | 385.6M | 652.8M | 1.1B | ||
Low | 352.2M | 460.4M | 851.6M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 56.0% | 105.1% | 168.4% | ||
Avg | 42.5% | 69.3% | 73.3% | ||
Low | 30.1% | 19.4% | 30.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -4.68 | 1.21 | 10.03 | ||
Avg | -5.66 | -2.01 | 4.45 | ||
Low | -6.28 | -4.95 | -2.05 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | ||
Avg | - | - | - | ||
Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.